Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Low-dose V180 with low-dose ISCOMATRIX adjuvant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Low-dose V180 with low-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Medium-dose Non-adjuvanted V180 | EXPERIMENTAL | - |
| Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Medium-Dose V180 with Alhydrogel™ adjuvant | EXPERIMENTAL | - |
| High-dose Non-adjuvanted V180 | EXPERIMENTAL | - |
| High-dose V180 with low-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| High-dose V180 with medium-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Low-dose V180 with high-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| High-dose V180 with high-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Low-dose V180 with low-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 (non-adjuvanted) | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 with Alhydrogel™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2 |
| High-dose V180 (non-adjuvanted) | BIOLOGICAL | Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2 |
| High-dose V180 with low-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| High-dose V180 with medium-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Low-dose V180 with high-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| High-dose V180 with high-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Placebo | BIOLOGICAL | Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2 |
Selected Inclusion Criteria: * In good health * Voluntarily agrees to participate by giving written informed consent * Able to read, understand, and complete study questionnaires * Able to complete all scheduled visits and comply with study procedures * Access to a telephone * Agrees to avoid unusu...
Top 2 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Qdenga |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
Low-dose V180 with low-dose ISCOMATRIX adjuvant is an investigational dengue vaccine candidate developed by Merck & Company, Inc. (MRK). It combines a low dose of the V180 dengue vaccine antigen with a low dose of the ISCOMATRIX adjuvant, a formulation designed to be evaluated in healthy adult volunteers in a Phase 1 clinical trial.
Low-dose V180 with low-dose ISCOMATRIX adjuvant is being studied for the prevention of dengue, an infectious disease caused by dengue virus. The Phase 1 trial enrolled healthy adults aged 18 years and older to evaluate this vaccine formulation against dengue.
Merck & Company, Inc., which trades under the ticker MRK, is the developer of low-dose V180 with low-dose ISCOMATRIX adjuvant. The company sponsored the Phase 1 study of this dengue vaccine candidate.
Low-dose V180 with low-dose ISCOMATRIX adjuvant is in Phase 1 clinical development. The single Phase 1 trial, NCT01477580, has been completed, and the candidate remains investigational rather than approved.
Low-dose V180 with low-dose ISCOMATRIX adjuvant was evaluated in one Phase 1 trial, NCT01477580, titled Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001). The trial enrolled 98 healthy adult volunteers, was randomized, double-blind, and placebo-controlled, and has been completed.